Other alterations, such as KNG1, PLD1, GNB4, PIK3CA, TERC, NFE2L2, DVL3, FGF12, and MECOM, which are also dysregulated in other cancers [76,77,78,79,80,81,82,83,84,85], showed co-amplification in CHRNB4-high patients, promoting cell survival and growth. Here, PLD1 is linked to cancer.